Monday, January 17, 2022
If you love a good mystery, let me try to draw you in to the enigma of Genapsys' business strategy. Genapsys presented last week at J.P. Morgan, but nobody who wasn't there knows what they said or presented. Keeping their future plans hush-hush is a strange course for a company that hasn't caught fire and is about to face multiple well-funded new competition.
Wednesday, January 12, 2022
Illumina's J.P. Morgan presentation was largely focused on various applications of their platform. But on the further platform development side, they did throw out two new products as very, very limited descriptions: Chemistry X as the future of sequencing-by-synthesis and Infinity for 10 kilobase synthetic reads. Both have triggered a lot of speculation and indeed some very clever sleuthing, since neither really had anything but the faintest of details provided
Tuesday, January 11, 2022
To my readers: I am quite embarrassed by the multiple errors which were present in the first two postings of the year, which include incomplete sentences in jumbled paragraphs, small but key errors of fact and writing "short read" in a key place where I meant "long read'. They are the sort of errors I can be quite harsh on others making. I put too much emphasis on pushing these out and far, far too little on proofreading and reviewing them. You deserve better.
Thursday, January 06, 2022
Theral Timpson hosted PacBio CEO Christian Henry and Invitae CEO Sean George for a Mendelspod podcast back on Pearl Harbor day last month. It's a fun, chatty interview with the two which illustrated why these two companies have an excellent strategic fit. I won't summarize all of it, but I did have strong reactions to three points
Monday, January 03, 2022
It looks like 2022 might be an exciting year for the short read genomics market, with new players taking on Illumina. J.P. Morgan will be virtual next week, so perhaps some of the players will make some announcements. Here's some thoughts on the situation as it stands now in a space where many of failed before -- QIAGEN, ThermoFisher (SOLiD) and Roche(454) -- as well as some have bailed out before even entering -- Agilent.
Friday, December 31, 2021
As the year closes out for me (as I write this, it may well have closed out for some of you!) I'm reflecting on some anniversaries that were concentrated in this year, particularly those that are multiples of an early evolutionary developmental decision millions of years ago.
Monday, December 13, 2021
Oxford Nanopore held their annual Community Meeting online at the beginning of this month. As is typical for this stage of the ONT news cycle, most topics were confirmations and updates of earlier projections, with little brand new material. There was one surprise, a new concept for running nanopore with little to no auxiliary lab equipment. Oh, and perhaps in the surprise category is Oxford appears to be finally moving away from the R9 pore which has been their mainstay for many years now.